Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded by StockNews.com to “Hold”

Cyclacel Pharmaceuticals (NASDAQ:CYCCGet Free Report) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

Separately, Roth Mkm reduced their price objective on shares of Cyclacel Pharmaceuticals from $21.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, May 3rd.

Read Our Latest Report on Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Stock Down 6.0 %

Shares of Cyclacel Pharmaceuticals stock opened at $1.88 on Tuesday. The company’s fifty day simple moving average is $2.09 and its two-hundred day simple moving average is $2.58. Cyclacel Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $13.20. The firm has a market cap of $2.75 million, a PE ratio of -0.08 and a beta of 0.58.

Cyclacel Pharmaceuticals (NASDAQ:CYCCGet Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($2.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.93) by $2.66. Cyclacel Pharmaceuticals had a negative return on equity of 1,009.04% and a negative net margin of 4,401.34%. The company had revenue of $0.03 million for the quarter. During the same quarter in the prior year, the firm earned ($7.05) EPS. As a group, sell-side analysts expect that Cyclacel Pharmaceuticals will post -4.93 earnings per share for the current fiscal year.

Cyclacel Pharmaceuticals Company Profile

(Get Free Report)

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.

Read More

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.